Evidence map›Paper›PMID 42043489›Full record

ArticleAmerican journal of clinical dermatology2026

48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients.

Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Teppei HaginoDepartment of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan. teppei-hagino@nms.ac.jp.ORCID http://orcid.org/0000-0002-4183-9596
Akihiko UchiyamaDepartment of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Hidehisa SaekiDepartment of Dermatology, Nippon Medical School, Tokyo, Japan.
Eita FujimotoDepartment of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.
Sei-Ichiro MotegiDepartment of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Naoko KandaDepartment of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn anti-interleukin (IL)‑13 antibody, lebrikizumab, has shown efficacy in the treatment of atopic dermatitis (AD). However, real‑world data on 1‑year transition of clinical and laboratory indices are limited.

objectivesTo evaluate the 48‑week transition of clinical and laboratory indices during lebrikizumab treatment in Japanese patients with moderate‑to‑severe AD, stratified by the presence or absence of prior systemic therapy.

methodsWe conducted a two‑center prospective study of 187 Japanese patients with AD treated with lebrikizumab. Clinical and laboratory indices were assessed until week 48 in systemic therapy-naive and -experienced patients.

resultsLebrikizumab reduced total and anatomical site-specific eczema area and severity index (EASI) and the peak pruritus numerical rating scale (PP‑NRS) throughout the 48 weeks. The magnitude of decreasing head and neck EASI was slightly lower in systemic therapy-experienced patients. Week 48 achievement rates of EASI 75, EASI 90, and PP‑NRS 4 were 84%, 61.8%, and 79.3% in systemic therapy-naive patients, and 68.8%, 41.7%, and 75% in systemic therapy-experienced patients, respectively. Lebrikizumab decreased immunoglobulin E, thymus and activation-regulated chemokine, and lactate dehydrogenase throughout 48 weeks.

conclusionIn a 48‑week real‑world practice, lebrikizumab showed favorable effectiveness for AD, with higher responses in systemic therapy-naive patients compared with systemic therapy-experienced patients, including in head and neck lesions.

Indexed as

Antibodies, MonoclonalDermatitis, AtopicDermatologic AgentsPruritusAdolescentAdultAntibodies, Monoclonal, HumanizedChemokine CCL17ChildFemaleHumansImmunoglobulin EJapanMaleMiddle AgedProspective StudiesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCCL17 protein, humanChemokine CCL17Dermatologic AgentsImmunoglobulin Elebrikizumab

Identifiers

PMID42043489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.